3-10142181-T-C
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000551.4(VHL):c.334T>C(p.Tyr112His) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Y112C) has been classified as Likely pathogenic.
Frequency
Genomes: not found (cov: 33)
Consequence
VHL
NM_000551.4 missense
NM_000551.4 missense
Scores
10
6
2
Clinical Significance
Conservation
PhyloP100: 5.01
Genes affected
VHL (HGNC:12687): (von Hippel-Lindau tumor suppressor) This gene encodes a component of a ubiquitination complex. The encoded protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. In addition to oxygen-related gene expression, this protein plays a role in many other cellular processes including cilia formation, cytokine signaling, regulation of senescence, and formation of the extracellular matrix. Variants of this gene are associated with von Hippel-Lindau syndrome, pheochromocytoma, erythrocytosis, renal cell carcinoma, and cerebellar hemangioblastoma. [provided by RefSeq, Jun 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PM1
In a hotspot region, there are 13 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 11 uncertain in NM_000551.4
PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chr3-10142181-T-A is described in ClinVar as [Pathogenic]. Clinvar id is 2228.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.99
PP5
Variant 3-10142181-T-C is Pathogenic according to our data. Variant chr3-10142181-T-C is described in ClinVar as [Pathogenic]. Clinvar id is 2222.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
VHL | NM_000551.4 | c.334T>C | p.Tyr112His | missense_variant | 1/3 | ENST00000256474.3 | |
VHL | NM_001354723.2 | c.334T>C | p.Tyr112His | missense_variant | 1/3 | ||
VHL | NM_198156.3 | c.334T>C | p.Tyr112His | missense_variant | 1/2 | ||
VHL | NR_176335.1 | n.404T>C | non_coding_transcript_exon_variant | 1/4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
VHL | ENST00000256474.3 | c.334T>C | p.Tyr112His | missense_variant | 1/3 | 1 | NM_000551.4 | P1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
GnomAD4 exome Cov.: 32
GnomAD4 exome
Cov.:
32
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Von Hippel-Lindau syndrome Pathogenic:3
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 1996 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia | Aug 01, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 28, 2018 | Variant summary: VHL c.334T>C (p.Tyr112His) results in a conservative amino acid change located in the von Hippel-Lindau disease tumour suppressor, beta/alpha domain of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 217656 control chromosomes. c.334T>C has been reported in the literature in multiple individuals affected with Von Hippel-Lindau Syndrome including a large kindred comprised of 107 people with or at-risk for VHL, of whom 49 have been diagnosed and 35/49 (71%) are clinically affected (Nielsen_2011). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic. - |
VHL-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | May 05, 2023 | The VHL c.334T>C variant is predicted to result in the amino acid substitution p.Tyr112His. This variant also described using legacy nomenclature as c.547T>C, p.Y111H; has been well-documented to be pathogenic for Type 2A von Hippel-Lindau disease (VHL) with pheochromocytoma (Chen et al. 1995. PubMed ID: 7728151; Zbar et al. 1996. PubMed ID: 8956040; Nielsen et al. 2011. PubMed ID: 21204227). Functional studies showed that this variant affects VHL function (Rathmell et al. 2004. PubMed ID: 15574766; Hacker et al. 2008. PubMed ID: 19030229). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant is interpreted as pathogenic. - |
Von Hippel-Lindau syndrome;C1837915:Chuvash polycythemia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jan 09, 2024 | This sequence change replaces tyrosine, which is neutral and polar, with histidine, which is basic and polar, at codon 112 of the VHL protein (p.Tyr112His). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with pheochromocytoma in two families and has been found in an independent family affected with the same condition (PMID: 7728151, 8863170, 21204227). It has also been observed to segregate with disease in related individuals. This variant is also known as c.547T>C, p.Y111H. ClinVar contains an entry for this variant (Variation ID: 2222). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt VHL protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects VHL function (PMID: 15574766, 19030229, 24002598). This variant disrupts the p.Tyr112 amino acid residue in VHL. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10533030, 11331613, 19602254). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 01, 2021 | The p.Y112H pathogenic mutation (also known as c.334T>C), located in coding exon 1 of the VHL gene, results from a T to C substitution at nucleotide position 334. The tyrosine at codon 112 is replaced by histidine, an amino acid with similar properties. This variant has been associated with Type 2A VHL and reported to segregate with pheochromocytoma in two large families and has been found in another independent family affected with pheochromocytoma and angiomas (Tisherman SE et al. Arch Intern Med, 1993 Nov;153:2550-6; Chen F et al. Hum Mutat, 1995;5:66-75; Chen F et al. J Med Genet, 1996 Aug;33:716-7; Nielsen SM et al. Am J Med Genet A, 2011 Jan;155A:168-73). Experimental studies have shown that this alteration results in an intermediate degree of HIF regulation in VHL null murine embryonic stem cell expression system and also leads to an increased microvessel density in a mouse model for teratoma analysis (Rathmell WK et al. Cancer Res, 2004 Dec;64:8595-603; Hacker KE et al. PLoS One, 2008 Nov;3:e3801). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
D;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
T;T
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D
MetaSVM
Pathogenic
D
MutationAssessor
Uncertain
M;M
MutationTaster
Benign
D;N
PrimateAI
Pathogenic
D
PROVEAN
Uncertain
D;N
REVEL
Pathogenic
Sift4G
Uncertain
D;D
Polyphen
D;D
Vest4
MutPred
Gain of disorder (P = 0.0205);Gain of disorder (P = 0.0205);
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at